EP-300

EP-300 is a preclinical-stage targeted membrane-disrupting peptide conjugate developed by Esperance Pharmaceuticals, which was originally discovered at Louisiana State University. It consists of a follicle-stimulating hormone (FSH) beta chain segment conjugated to the cationic lytic peptide Phor18. EP-300 is designed to target follicle-stimulating hormone receptors (FSHR) overexpressed on the surface of cancer cells and the endothelial cells of blood vessels supplying tumors. Upon binding to FSHR, the lytic peptide component disrupts the cell membrane, leading to rapid cell lysis and necrosis. This dual mechanism provides both direct antineoplastic activity and anti-angiogenic effects, making it a potential therapeutic candidate for the treatment of various solid tumors.